Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of R-Terfenadine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 3/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 1.00 |
| ▸ | DRD3 | P35462 | 3/20 | 1.00 |
| ▸ | HTR2A | P28223 | 2/20 | 1.00 |
| ▸ | HTR2B | P41595 | 2/20 | 1.00 |
| ▸ | BLM | P54132 | 2/20 | 1.00 |
| ▸ | DRD2 | P14416 | 2/20 | 1.00 |
| ▸ | CYP2J2 | P51589 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | NPC1 | O15118 | 1/20 | 1.00 |
| ▸ | CACNA1F | O60840 | 1/20 | 1.00 |
| ▸ | GMNN | O75496 | 1/20 | 1.00 |
| ▸ | USP2 | O75604 | 1/20 | 1.00 |
| ▸ | EGFR | P00533 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | FYN | P06241 | 1/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | ABCB1 | P08183 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Terfenadine SCHEMBL5152 | 1.00 | KCNH2 (1.00) | KCNH2LMNAHRH1DRD3HTR2A | |
| Terfenadine SCHEMBL5998456 | 1.00 | KCNH2 (1.00) | KCNH2LMNAHRH1DRD3HTR2A | |
| Terfenadine SCHEMBL5999023 | 1.00 | KCNH2 (1.00) | KCNH2LMNAHRH1DRD3HTR2A | |
| Terfenadine SCHEMBL5999024 | 1.00 | KCNH2 (1.00) | KCNH2LMNAHRH1DRD3HTR2A | |
| SCHEMBL11857869 | 1.00 | KCNH2 (1.00) | KCNH2LMNAHRH1DRD3HTR2A | |
| R-Terfenadine SCHEMBL17732284 | 0.99 | KCNH2 (0.98) | KCNH2LMNAHRH1DRD3HTR2A | |
| Terfenadine SCHEMBL11546558 | 0.99 | KCNH2 (0.98) | KCNH2LMNAHRH1DRD3HTR2A | |
| Terfenadine SCHEMBL27965234 | 0.99 | KCNH2 (0.98) | KCNH2LMNAHRH1DRD3HTR2A | |
| Terfenadine SCHEMBL17732283 | 0.99 | KCNH2 (0.98) | KCNH2LMNAHRH1DRD3HTR2A | |
| SCHEMBL11871354 | 0.98 | KCNH2 (0.96) | KCNH2LMNAHRH1DRD3HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3906 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12617809-B2 | Cardioprotective lipid and method of use | SIGNPATH PHARMA, INC. (US) | 2026-05-05 | — | — | US | claimed |
| EP-4658278-A1 | SELECTIVE FIASMA TREATMENT | Valo Health, Inc. (US) | 2025-12-10 | — | — | EP | claimed |
| US-12474326-B2 | Treatment methods having reduced drug-related toxicity and methods of identifying the likelihood of patient harm from prescribed medications | TABULA RASA HEALTHCARE, INC. (US) | 2025-11-18 | — | — | US | claimed |
| EP-4590681-A1 | CARDIOPROTECTIVE LIPID AND METHOD OF USE | Signpath Pharma, Inc. (US) | 2025-07-30 | — | — | EP | claimed |
| WO-2025049064-A9 | CARDIOPROTECTIVE LIPIDS AND METHODS OF USE | SIGNPATH PHARMA INC. (US) | 2025-05-22 | — | — | WO | claimed |
| US-20250129430-A1 | HIGH ATP-AFFINITY PROTEIN AS THERAPEUTIC TARGET FOR INTRACTABLE CANCER MOLECULAR SUBTYPES AND INHIBITOR THEREOF | VeraVerse Co., Ltd. (KR) | 2025-04-24 | — | — | US | claimed |
| WO-2025049064-A2 | CARDIOPROTECTIVE LIPIDS AND METHODS OF USE | SIGNPATH PHARMA INC. (US) | 2025-03-06 | — | — | WO | claimed |
| EP-4442840-A1 | HIGH ATP-AFFINITY PROTEIN AS THERAPEUTIC TARGET FOR INTRACTABLE CANCER MOLECULAR SUBTYPES AND INHIBITOR THEREOF | Veraverse Co., Ltd. (KR) | 2024-10-09 | — | — | EP | claimed |
| US-20240270765-A2 | CARDIOPROTECTIVE LIPIDS AND METHODS OF USE | SIGNPATH PHARMA INC. | 2024-08-15 | — | — | US | claimed |
| US-20240263135-A1 | COMPOSITIONS AND METHODS FOR IMMUNE CELL MODULATION IN ADOPTIVE IMMUNOTHERAPIES | FATE THERAPEUTICS, INC. | 2024-08-08 | — | — | US | claimed |
| WO-1999008676-A1 | COMPOSITIONS CONTAINING BERGAMOTTIN FOR INCREASING THE ORAL BIOAVAILABILITY OF PHARMACEUTICAL AGENTS | WARNER-LAMBERT COMPANY (US) | 1999-02-25 | — | — | WO | claimed |
| CN-1189774-A | Controlled release formulations for poorly soluble drugs | ELAN CORP PLC (IE) | 1998-08-05 | — | — | CN | claimed |
| US-5691370-A | 5-(2-imidazolinylamino)benzimidazole compounds useful as alpha-2-adrenoceptor agonists | THE PROCTER & GAMBLE COMPANY (US) | 1997-11-25 | — | — | US | claimed |
| CN-1152431-A | Dry syrup of teldane | XIAO XUECHENG (CN) | 1997-06-25 | — | — | CN | claimed |
| EP-0759904-A1 | PROCESS AND DIASTEREOMERIC SALTS USEFUL FOR THE OPTICAL RESOLUTION OF RACEMIC ALPHA-[4-(1,1-DIMETHYLETHYL)PHENYL]-4-(HYDROXYDIPHENYLMETHYL)-1-PIPERIDINEBUTANOL AND DERIVATIVE COMPOUNDS | MERRELL PHARMACEUTICALS INC. (US) | 1997-03-05 | — | — | EP | claimed |
| WO-1995031436-A1 | PROCESS AND DIASTEREOMERIC SALTS USEFUL FOR THE OPTICAL RESOLUTION OF RACEMIC α-[4-(1,1-DIMETHYLETHYL)PHENYL]-4-(HYDROXYDIPHENYLMETHYL)-1-PIPERIDINEBUTANOL AND DERIVATIVE COMPOUNDS | MERRELL PHARMACEUTICALS INC. (US) | 1995-11-23 | — | — | WO | claimed |
| WO-1995007889-A1 | A PROCESS FOR THE PREPARATION OF POLYMORPH I OF THE TERFENADINE WITH AN OPTIMUM GRANULOMETRIC DISTRIBUTION | RECORDATI S.A. CHEMICAL AND PHARMACEUTICAL COMPANY (CH) | 1995-03-23 | — | — | WO | claimed |
| EP-0574424-A1 | NOVEL SALTS/ION PAIRS OF NON-STEROIDAL ANTI-INFLAMMATORY DRUGS IN VARIOUS DOSAGE FORMS | WARNER-LAMBERT COMPANY (US) | 1993-12-22 | — | — | EP | claimed |
| WO-1992015332-A1 | NOVEL SALTS/ION PAIRS OF NON-STEROIDAL ANTI-INFLAMMATORY DRUGS IN VARIOUS DOSAGE FORMS | WARNER-LAMBERT COMPANY (US) | 1992-09-17 | — | — | WO | claimed |
| EP-0173293-B1 | HOT MELT ANTIHISTAMINE FORMULATIONS | MERRELL DOW PHARMACEUTICALS INC. (US) | 1991-10-30 | — | — | EP | claimed |